Development, validation, and estimation of measurement uncertainty for the quantitative determination of nitrosamines in Sartan drugs using Liquid Chromatography-Atmospheric Pressure Chemical Ionization-Tandem Mass Spectrometry

[1]  M. Jain,et al.  A Critical N-Nitrosamine Impurity of Anticoagulant Drug, Rivaroxaban: Synthesis, Characterization, Development of LC–MS/MS Method for Nanogram Level Quantification , 2022, Chromatographia.

[2]  P. Rojsitthisak,et al.  Development of a Sensitive Headspace Gas Chromatography–Mass Spectrometry Method for the Simultaneous Determination of Nitrosamines in Losartan Active Pharmaceutical Ingredients , 2021, ACS omega.

[3]  G. Namjoshi,et al.  Nitrosodimethylamine impurities in metformin drug products: Physician insight , 2021 .

[4]  S. Tomic,et al.  Presence of Nitrosamine Impurities in Medicinal Products , 2021, Arhiv za higijenu rada i toksikologiju.

[5]  M. Heravi,et al.  Prescribed drugs containing nitrogen heterocycles: an overview , 2020, RSC advances.

[6]  A. Pandey,et al.  Estimation of measurement uncertainty for the quantitative analysis of pharmaceutical residues in river water using solid-phase extraction coupled with injector port silylation-gas chromatography-tandem mass spectrometry , 2020 .

[7]  Pramod Kumar,et al.  Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques , 2020, Critical reviews in analytical chemistry.

[8]  Ho‐Sang Shin,et al.  Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography-tandem mass spectrometry. , 2020, Journal of pharmaceutical and biomedical analysis.

[9]  Mei-Chih Lin,et al.  A multi-analyte LC-MS/MS method for screening and quantification of nitrosamines in sartans , 2020, Journal of food and drug analysis.

[10]  Tabrez Shaikh,et al.  Nitrosamine Impurities in Drug Substances and Drug Products , 2020 .

[11]  H. Akiyama,et al.  Rapid and efficient high-performance liquid chromatography analysis of N-nitrosodimethylamine impurity in valsartan drug substance and its products , 2019, Scientific Reports.

[12]  U. Holzgrabe,et al.  The contamination of valsartan and other sartans, part 1: New findings. , 2019, Journal of pharmaceutical and biomedical analysis.

[13]  H. Akiyama,et al.  Analysis of an Impurity, N-Nitrosodimethylamine, in Valsartan Drug Substances and Associated Products Using GC-MS. , 2019, Biological & pharmaceutical bulletin.

[14]  M. Parr,et al.  NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N‐nitrosamines , 2019, Journal of pharmaceutical and biomedical analysis.

[15]  Luciana Separovic,et al.  Using measurement uncertainty to assess the fitness for purpose of an HPLC analytical method in the pharmaceutical industry , 2018 .

[16]  L. Samson,et al.  Balancing repair and tolerance of DNA damage caused by alkylating agents , 2012, Nature Reviews Cancer.

[17]  J. Yu,et al.  Occurrence of nine nitrosamines and secondary amines in source water and drinking water: Potential of secondary amines as nitrosamine precursors. , 2011, Water research.

[18]  J. V. Sancho,et al.  Determination of eight nitrosamines in water at the ng L(-1) levels by liquid chromatography coupled to atmospheric pressure chemical ionization tandem mass spectrometry. , 2011, Analytica chimica acta.

[19]  S. Walfish.  A statistical perspective on the ICH Q2A and Q2B guidelines for validation of analytical methods , 2006 .

[20]  S. Ellison,et al.  Quantifying uncertainty in analytical measurement , 2000 .

[21]  E. Iso,et al.  Measurement Uncertainty and Probability: Guide to the Expression of Uncertainty in Measurement , 1995 .